News from phio pharmaceuticals corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 10, 2021, 08:30 ET Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Mar 25, 2021, 17:15 ET Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Mar 11, 2021, 07:30 ET Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Mar 01, 2021, 08:00 ET Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Feb 23, 2021, 07:30 ET Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Feb 17, 2021, 16:15 ET Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Feb 12, 2021, 07:00 ET Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Jan 25, 2021, 17:15 ET Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Jan 21, 2021, 15:33 ET Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Jan 04, 2021, 16:15 ET Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Nov 19, 2020, 07:30 ET Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Nov 10, 2020, 17:00 ET Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Nov 09, 2020, 08:00 ET Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Oct 26, 2020, 07:30 ET Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Sep 09, 2020, 07:05 ET Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Aug 12, 2020, 17:00 ET Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Jun 22, 2020, 09:00 ET Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Jun 08, 2020, 08:30 ET Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th

MARLBOROUGH, Mass., June 8, 2020 /PRNewsire/ – Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of...

May 29, 2020, 08:00 ET Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

May 14, 2020, 16:05 ET Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

May 12, 2020, 16:38 ET Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

May 04, 2020, 07:30 ET Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Apr 02, 2020, 12:15 ET Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Mar 31, 2020, 12:11 ET Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...

Mar 31, 2020, 07:30 ET Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...